Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds

Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.

Deals Financing Business Strategies

All Gifts Out As IFPMA New Code Of Practice Raises Ethical Bar

The international drug industry group's new code of practice bans gifts and promotional aids and moves from a rules-based approach to a so-called 'values-based' code in IFPMA's dealings with the overall healthcare community.

Commercial Companies Legal Issues
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Aptinyx Says DPN Setback Just A Step In Seeking Chronic Pain Indication

Investors reacted negatively when Aptinyx’s lead candidate missed its primary endpoint in diabetic peripheral neuropathy, but CEO Riedel tries to emphasize the positives from the study while awaiting fibromyalgia data with NYX-2925.

Neurology Research & Development

Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances

R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.

Leadership Companies

Pharma Industry Holds Tight As Disorderly Brexit Approaches

A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.

Brexit Trade

How Lilly Aims To Make Sure Good Drugs Don't Get Lost In Translation

SVP/CSO Daniel Skovronsky says the company has invested in technology and biotech-like teams to speed up the process of translating targets identified in house into human data for novel drugs.

Business Strategies Research and Development Strategies

Video: Novo Seeds Describes Company-Building Aspirations

With a focus on innovative early stage European biotechs, Novo Seeds senior partner Stephan Christgau explains to Scrip how the investor picks opportunities and creates companies.

Financing Companies

Takeda's Investments In Data Science Seek Improved Trial Outcomes, R&D Efficiency

President of R&D Andrew Plump notes that much of the work to rationalize Takeda's pipeline after its Shire acquisition took place years ago when the Japanese pharma streamlined its R&D organization, but investments in data science to improve clinical trial outcomes and R&D efficiency are ongoing.

Research and Development Strategies Artificial Intelligence
See All

Deals

Set Alert for Deals

Latest From Deals

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

US Army Splashes The Cash On Valneva's JE Vaccine

Valneva’s 2019 guidance has been boosted by the US Army’s Ixiaro vaccine order, as other products flourish in the pipeline.

Vaccines Deals

Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy

Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.

Deals Commercial

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
Commercial Deals

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts

Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: US generics see gains, researcher calls for more tech transfer, and biotech investor sentiment rises as big deals bring optimism – among other items from the last day of this year's JPM. 

Business Strategies Regenerative Medicine
See All

Strategy

Set Alert for Strategy

Latest From Strategy

AZ Management Shake-Up Sees CMO Bohen Exit

Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.

Leadership Strategy

Glenmark, Yuhan Partner for Ryaltris, Eyes On US Trajectory

Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
Commercial Deals

EUSA Sylvant Licence Marks Toehold Into US Rare Disease Market

Six months after selling its critical care business to refocus on rare diseases and oncology, EUSA Pharma has made its first move into those markets by licensing a Janssen product for a rare blood disorder.

Rare Diseases Deals

Pfizer Pulls Plug On Two Unviable Indian Sites, Over 1,500 Jobs At Risk

Pfizer is ending operations at two Indian manufacturing sites, including one with a checkered regulatory history. Approximately 1,700 jobs are at stake as a result of the action, though the US multinational clarified that it is not making a widespread exit from Indian manufacturing.
Commercial Strategy

India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)

2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.
Commercial Deals

Scrip Asks… What Does 2019 Hold For Biopharma? Part 2: Business Trends

What do biopharma leaders and experts expect for the coming year? Following on from therapeutic area insights in part 1, our interviewees consider the outlook for business trends, from M&A and financing to digital strategy, AI and organizational management.

Business Strategies Financing
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Pharma Industry Holds Tight As Disorderly Brexit Approaches

A worst-case Brexit scenario – a disorderly one – has become more likely, making an already white-knuckled life sciences industry step up its preparations.

Brexit Trade

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

Annual payment plans for gene therapies appear closer to becoming reality now that bluebird bio detailed plans at J.P. Morgan. Novartis, Sarepta and others are also talking to payers about alternative payment models. Harvard Pilgrim's Michael Sherman applauded the effort in an interview.

Market Access Pricing Strategies

Scrip Asks...What Does 2019 Hold For Biopharma? Part 3: Pricing, Reimbursement And Market Access

How much therapies should cost and how they should be reimbursed are questions that are expected to dominate in 2019, according to industry experts and participants surveyed by Scrip on their expectations for the coming year. This is the focus for the final installment of our three-part Scrip Asks series.

Pricing Debate Pricing Strategies
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Rovi and Recordati Deemed Top Picks By Analyst

The team at Jefferies believe that the Spanish and Italian firms, as well as Hikma, are looking like good bets for the year ahead.

Market Intelligence Europe

UroGen's Lead Product Data Back Barrett's Interest

UroGen's reverse thermal gel formulation of mitomycin produced a high rate of complete responses in patients with urothelial cancer; developing a commercialization strategy for the product will benefit from the experience of the company's new CEO.

 

Cancer Clinical Trials

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Innovation Market Intelligence
See All
UsernamePublicRestriction

Register